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Breast cancer is the most commonly diagnosed cancer in women and the
second most common overall. Extensive work has been done on the underlying
genetic mechanisms concerning the development of malignancy(Van't Veer et
al 2002), but the focus is shifting to reflect evidence that the tumor
microenvironment is critical to understanding the disease(Liao et al 2009). TGF-
B has been implicated in the induction of cancer associated fibroblasts and
subsequent development of cancer in breast epithelial cells (Kuperwasser et al
2004), and it is known to be stored in the fibronectin of the ECM via the LTBP-1
protein (Zilberberg 2012). With increased deposition of fibronectin in a
cancerous state (Cirri et al 2011), and knowing that TGF-B is stored in the
fibronectin matrix of the ECM, we propose that TGF-B in cooperation with the
biological matrix downregulates caveolin-1 in human mammary fibroblasts.
We believe that fibronectin matrix alone does not downregulate caveolin-1.
Additionally, we propose that TGF-β is stored in the biological matrix in the
form of LTBP-1, and, in cooperation with the matrix, downregulates cav-1 in
human mammary fibroblasts.
HMFs were plated on 6-well plates that were coated with varying densities of
ECM protein and observed for downregulation of caveolin-1 via Western Blot.
Additionally, LTBP-1 was visualized using immunofluorescence with DAPI to
visualize the nucleus , GFP to visualize LTBP-1, and RFP to visualize the
fibronectin. Additionally, to observe the effects of TGF-β on caveolin-1
expression levels, HMFs were plated on a control plate or biological ECM and
observed for 24, 48, and 72 hours then collected and lysed to quantify protein
expression with Western Blot.
Immunofluorescence was used to identify LTBP-1 presence in both HMFs and biological ECM
harvested from HMFs. LTBP is shown stained using GFP in both HMFs (A) and ECM (D). DAPI
was used to stain HMF nuclei (B). These images were merged to demonstrate the presence
of LTBP in the cells and ECM (C). GFP was separately used to image fibronectin in the ECM
deposited from HMFs (E). To further verify the presence of LTBP-1 in HMFs, western blot was
used. Here, faint bands at 240kDa verify that the protein is expressed in this cell type.
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 Cav-1 is not downregulated through fibroblast interaction with the
fibronectin matrix alone
 LTBP-1 is present in HMFs and more specifically in the biological ECM as
evidenced via western blot and immunofluorescence
 TGF-β decreases cav-1 expression in HMFs grown on a biological matrix and
not control plates, indicating a mechanism of cav-1 downregulation via TGF-
β interaction with the matrix
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HMFs grown for 24 hours on a control plate and a plate of biological ECM treated with TGF- β yielded no significant changes in caveolin-1 expression (A-D).  Likewise, HMFs grown for 72 hours on a 
control plate and treated with TGF-β yielded no significant changes in cav-1 expression. However, HMF grown on biological matrix for 72h and treated with TGF-β shows significant downregulation of 
caveolin-1, results that are compounded with increasing concentrations of TGF-β with a p-value of p<0.0001 as tested by ANOVA. This is indicative of a time-dependent downregulation of cav-1.
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HMFs grown on varying densities of pure fibronectin (5ug/ml, 10ug/ml, 20 ug/ml) , laminin 
(1ug/ml, 2 ug/ml, 5 ug/ml), vitronectin (5ug/ml, 10ug/ml, 20 ug/ml), and collagen 1 
(5ug/ml, 10ug/ml, 20 ug/ml) matrices showed no significant downregulation in caveolin-1 
expression after 24 hours (A-C) or 48 hours (D-F). Further investigation on a very dense 
fibronectin matrix (40 ug/ml) derived from human plasma yielded no significant changes in 
caveolin-1 expression (G-H). 
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